Highest-materiality recent filing
NeoGenomics appoints Carolyn Starrett, former Flatiron Health CEO, to board
Board expanded from 9 to 10 directors; Starrett fills new seat effective June 23, 2026.
NeoGenomics issues $316.25M of 0.75% convertible notes due 2032, repurchases $276M of existing notes
Issued $316.25M aggregate principal of 0.75% Convertible Senior Notes due 2032, conversion price ~$14.16 (35% premium to $10.49 close).
NeoGenomics prices $275M convertible notes due 2032; to repurchase $276M of existing notes
$275M principal of 0.75% convertible notes due 2032; initial purchasers have option for additional $41.25M.
NeoGenomics commences $275M convertible note offering due 2032
Offering $275M aggregate principal amount of convertible senior notes due 2032, with option for additional $41.25M.
NeoGenomics stockholders approve 5M share increase to 2023 equity plan, elect all director nominees
All nine director nominees elected; Lynn Tetrault received 105.7M votes for (96.9% of votes cast).
NeoGenomics Q1 revenue up 11% to $187M; raises FY2026 guidance to $797-803M
Consolidated revenue $187M (+11% YoY); Clinical revenue +14%, NGS +26%.
Q4 consolidated revenue $190M (+11% YoY); full-year revenue $727M (+10% YoY); clinical revenue grew 15% excluding Pathline.
Preliminary Q4 2025 revenue ~$190M (+11% YoY); full-year 2025 revenue ~$727M (+10% YoY).
NeoGenomics appoints Jack Kenny to board; Dr. Alison Hannah departs after 10 years
Dr. Alison Hannah resigns from NeoGenomics board effective Dec 31, 2025, after over 10 years of service.
NeoGenomics Q3 revenue up 12% to $188M; net loss widens 53% to $27M
Revenue of $188M, +12% YoY; clinical revenue +18% and NGS +24% to ~1/3 of clinical.
Director Elizabeth Floegel resigns from NeoGenomics Board effective August 5, 2025
Elizabeth Floegel resigned from the Board of Directors effective August 5, 2025.
NeoGenomics Q2 revenue up 10% to $181M but net loss widens to $45M; cuts full-year guidance
Revenue $181M (+10% YoY); clinical revenue grew 16% (13% ex-Pathline).
NeoGenomics appoints Merck oncology head Dr. Marjorie Green to board
Dr. Marjorie C. Green appointed to NeoGenomics board effective June 19, 2025; board expands from 9 to 10 members.
NeoGenomics shareholders approve 4.325M share increase to 2023 Equity Plan, all directors re-elected
Amendment to 2023 Equity Incentive Plan approved: +4.325M shares, 1-year minimum vesting, no liberal share recycling.
NeoGenomics Q1 revenue up 8% to $168M; adjusted EBITDA turns positive at $7M
Consolidated revenue $168M (+8% YoY); net loss improved 4% to $26M.
NeoGenomics amends bylaws to tighten advance notice rules for stockholder director nominations
Stockholder nominations must be received 90-120 days before anniversary of prior annual meeting.
NeoGenomics finalizes CEO Zook employment agreement: $850K salary, 100% bonus target, $8M equity
Base salary of $850,000 per year, effective April 1, 2025, subject to Board adjustment.
NeoGenomics promotes Warren Stone to President & COO; Melody Harris to depart
Warren Stone promoted to President & COO effective April 1, 2025; previously CCO.
NeoGenomics promotes Warren Stone to President & COO; COO Melody Harris to depart in May
Warren Stone promoted from CCO to President & COO effective April 1, 2025; retains commercial duties and adds lab operations, data solutions, enterprise operations.
NeoGenomics Q4 revenue +11% to $172M; FY24 $661M; guides FY25 rev $735-745M
Q4 consolidated revenue $172M (up 11% YoY); net loss $15M vs $14M in Q4 2023.
NeoGenomics guides 2025 revenue $735-745M, adj. EBITDA $55-58M; issues retention bonuses
2025 revenue guidance $735-745M (midpoint $740M) vs FY24 $661M, ~12% YoY growth.
NeoGenomics CEO Chris Smith to retire April 1; board member Tony Zook named successor
Chris Smith retires as CEO effective April 1, 2025; will serve as special advisor through Feb 2027 at $23,913/month.
NeoGenomics Q3 revenue up 10% to $168M; adjusted EBITDA up 305%, raises FY guidance to $37-40M
Consolidated revenue $168M (+10% YoY); Clinical Services revenue $146M (+14%) with test volume +9%.
NeoGenomics Q2 revenue $165M (+12% YoY); raises FY2024 EBITDA guidance to $33-37M
Q2 revenue $165M (+12% YoY); net loss narrowed 23% to $19M.
NeoGenomics annual meeting elects all 9 directors, passes say-on-pay with 69.5% support
117.6M shares (92.1% of outstanding) voted at May 23, 2024 annual meeting.
NeoGenomics Q1 revenue up 14% to $156M; Adjusted EBITDA turns positive at $3M
Clinical Services revenue rose 17% to $135M; test volume up 5% YoY, revenue per test up 11% to $447.
NeoGenomics eliminates President, Advanced Diagnostics role; promotes Harris and Stone
Vishal Sikri steps down as President, Advanced Diagnostics; role eliminated in restructuring.
NeoGenomics files 8-K/A solely to add Cover Page XBRL tagging; no change to prior disclosure
Amendment to Feb 23, 2024 8-K adds Inline XBRL tagging on cover page only.
NeoGenomics adopts new performance-based RSU award agreement form
Culture & Compensation Committee authorized new form of PSU agreement under 2023 Equity Incentive Plan on Feb 16, 2024.
NeoGenomics Q4 revenue $156M (+12% YoY); FY loss narrows 39% to $88M; guides FY24 rev $650-660M
Q4 consolidated revenue $156M (+12% YoY); Clinical Services +20% to $130M, Advanced Diagnostics -17% to $25M.
NeoGenomics Q3 revenue up 18% to $152M, net loss halved, raises FY guidance
Consolidated revenue $152M (+18% YoY); Clinical Services $128M (+20%), Advanced Diagnostics $24M (+8%).
NeoGenomics Q2 revenue up 18% to $147M; net loss narrows 31% to $24M
Revenue of $147M (+18% YoY); Clinical Services $123M (+17%), Advanced Diagnostics $24M (+22%).
NeoGenomics appoints three independent directors to board
Rachel Stahler resigned from the Board effective June 26, 2023; no disagreement with company.
NeoGenomics annual meeting: all directors elected; say-on-pay passes with 51.79% support
Eight directors elected with votes For ranging from 97.2M (Kelly) to 105.7M (Smith).
NeoGenomics adopts new PSU award form, grants $250K relocation to President Harris
New form of performance-based RSU agreement ties vesting to absolute total shareholder return (stock price targets).
NeoGenomics Q1 revenue up 17% to $137M; narrows net loss; raises FY2023 guidance
Consolidated revenue $137M (+17% YoY); Clinical +16% to $115M, Pharma +22% to $22M.
NeoGenomics posts investor presentation; full content not provided in filing
Investor presentation furnished as Exhibit 99.1 to the 8-K.
Q4 revenue $139M (+10% YoY); full year revenue $510M (+5% YoY).
Director David J. Daly resigns from NeoGenomics Board effective Jan 19, 2023
David J. Daly resigned from the Board immediately; no reason other than not due to disagreement.
NeoGenomics appoints Jeffrey S. Sherman as CFO; William Bonello steps down
Jeffrey S. Sherman named CFO effective Dec 7, 2022; William Bonello remains as employee for transition support.
NeoGenomics appoints Melody Harris as President, Enterprise Operations
Melody Harris, age 56, appointed as President, Enterprise Operations effective Dec 5, 2022.
NeoGenomics Q3 revenue $129M (+6%); net loss widens to $37M, adjusted EBITDA -$12M
Revenue $129M (+6% YoY); Clinical Services $106M (+4%), Pharma Services $23M (+18%).
NeoGenomics appoints David Perez to board, Warren Stone as clinical services president
David B. Perez appointed to Board effective Nov 3, 2022; term until 2023 annual meeting.
NeoGenomics grants retention agreement to CAO Cynthia Dieter worth $250K
Cash retention bonus of $150,000, payable 50% on Mar 31, 2023 and 50% on May 31, 2023, subject to continued employment.
Amendment provides incoming CEO Christopher Smith restricted stock inducement with target value of approximately $3,350,000.
NeoGenomics Q2 revenue $125M (+3%), net loss $35M; appoints Chris Smith CEO
Revenue $125M (+3% YoY); Clinical $106M (+4%), Pharma $19M (-4%). Net loss $35M vs $76M income (incl $97M Inivata gain).
NeoGenomics appoints Chris Smith as CEO effective Aug 15, 2022; Tetrault resumes Chair
Chris Smith, former CEO of Ortho Clinical Diagnostics, appointed CEO effective August 15, 2022.
NeoGenomics subsidiary settles with former CEO Clive Morris for £607,500 in termination payments
Settlement includes £202,500 payment in lieu of notice, £303,750 retention cash bonus component, and £101,250 pro-rated MIP bonus.
NeoGenomics say-on-pay fails at 2022 annual meeting; directors elected
Say-on-pay received 30.6% for vs 68.9% against (advisory, non-binding).
NeoGenomics appoints Lynn Tetrault as Interim CEO; Chief Strategy Officer departing May 27
Lynn Tetrault named Chair of the Board and Interim CEO, effective May 12, 2022; no compensation change.
On June 19, 2025, the Board of Directors of NeoGenomics, Inc. (the "Company") increased the size of the Board of Directors (the "Board") from nine to ten members and appointed Marjorie C. Green as a director to fill the vacancy resulting from that increase.
On March 18, 2025, NeoGenomics, Inc. (the "Company") announced the promotion of Warren Stone, the Company's current Chief Commercial Officer, to the position of President & Chief Operating Officer, effective April 1, 2025.
Additionally, on March 18, 2025, the Company announced that the Chief Operations Officer and President, Oncology Data Solutions position is being eliminated and as a result, Melody Harris, the current Chief Operations Officer and President, Oncology Data Solutions will no longer hold such role effective April 1, 2025.
Additionally, on March 18, 2024, the Company announced that the Chief Operations Officer position is being eliminated and as a result, Melody Harris, the current Chief Operations Officer, will no longer hold such role and will no longer be a named executive officer effective April 1, 2025.
On March 18, 2025, NeoGenomics, Inc. (the "Company") announced the promotion of Warren Stone, the Company's current Chief Commercial Officer, to the position of President & Chief Operating Officer, effective April 1, 2025.
The Special Advisor Agreement provides that Mr. Smith will serve as a special advisor to the Company’s Chief Executive Officer until February 26, 2027 in exchange for a fee of $23,913 per month.
Christopher Smith, the Company’s Chief Executive Officer and a member of the Company’s board of directors (the “Board”), will retire effective April 1, 2025
Christopher Smith, the Company’s Chief Executive Officer and a member of the Company’s board of directors (the “Board”), will retire effective April 1, 2025
On January 10, 2025, the Company announced the appointment of Tony Zook to replace Mr. Smith as Chief Executive Officer effective April 1, 2025.
On November 1, 2024, the Board of Directors of the Company, appointed Felicia Williams to serve as a member of the Board, the Company’s Audit and Finance Committee (the “Audit Committee”) and the Company’s Nominating and Corporate Governance Committee (the “NCG Committee”).
as a result, Vishal Sikri, the current President, Advanced Diagnostics, will no longer hold such role
Melody Harris, presently the Company's President, Enterprise Operations will now serve as the Company's Chief Operations Officer and President, Informatics.
Max materiality 0.85 · Median 0.57 · Most common event leadership